Report from Orexo AB’s Annual General Meeting, 15 April

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Apr 15, 2016 at 1:45 PM

Report from Orexo AB’s Annual General Meeting, 15 April 2016

Election of the board of directors and auditor The annual general meeting in Orexo AB (publ) on 15 April 2016 resolved, in accordance with the nomination committee's proposal, that the number of board members shall be seven with no deputy board members. Raymond Hill, Staffan Lindstrand, Martin Nicklasson, Kristina Schauman, Michael Shalmi and David Colpman were re-elected as ordinary board members. Kirsten Detrick was elected as a new board member. Martin Nicklasson was re-elected as chairman of the board. Ernst & Young Aktiebolag was elected as auditor. Fees to the board of directors and the auditor The annual general meeting also resolved on fees to the board of directors in accordance with the nomination committee's proposal. The fees to the board of directors shall amount to SEK 2,100,000 to be allocated as follows: SEK 600,000 to the chairman, and SEK 200,000 to each of the other board members, and in total SEK 300,000 to be allocated to the members of the audit committee so that the chairman of the committee receives SEK 200,000 and SEK 100,000 are allocated between the other members of the committee, that fees to the auditor shall be paid against approved accounts, and that fees to the board members may, if agreed with Orexo, be invoiced by a company, in which case the invoiced fee shall be determined so that it is cost neutral for Orexo. Remuneration guidelines for the management The annual general meeting approved the board of directors’ proposal regarding guidelines for remuneration to the management. Nomination committee The annual general meeting resolved to appoint a nomination committee for the annual general meeting 2017 substantially in accordance with the same procedure as the preceding year. Approval of income statement and balance sheets, appropriation of the company’s profit or loss and discharge from liability The annual general meeting approved the income statement and the balance sheet for the parent company, as well as the consolidated income statement and the consolidated balance sheet for the financial year 2015. It was resolved, in accordance with the board of directors’ proposal, that there shall be no dividend for 2015 and that the results of the company shall be carried forward. The meeting also discharged the members of the board and the managing director from liability for the financial year 2015. Authorization to issue new shares The annual general meeting resolved to authorizes the Board of Directors to resolve to issue of new shares on one or several occasions until the next annual general meeting, with or without preferential rights for the shareholders, against cash payment or against payment through set-off or in kind, or otherwise on special conditions. However, such issue of shares must never result in the company’s issued share capital or the number of shares in the company at any time, being increased by more than a total of 10 per cent. The purpose of the authorization is to enable the Board to make corporate acquisitions, product acquisitions or to enter into collaboration agreements, or to raise working capital or broaden the shareholder base. Authorization to repurchase and transfer shares The annual general meeting resolved to authorize the board of directors to resolve to repurchase, on one or several occasions until the next annual general meeting, as many own shares as may be purchased without the company’s holding at any time exceeding 10 per cent of the total number of shares in the company. Further, it was resolved to authorize the board of directors to resolve, on one or several occasions until the next annual general meeting, to transfer (sell) own shares. The purpose of the authorization to repurchase own shares is to promote efficient capital usage in the company and to provide flexibility as regards the company’s possibilities to distribute capital to its shareholders. The purpose of the authorization to transfer own shares is to enable the Board to make corporate acquisitions, product acquisitions or enter into collaboration agreements, or to raise working capital or broaden the shareholder base or for use in the context of the company’s incentive plans. Long-term incentive program The annual general meeting resolved, in accordance with the board's proposal, to adopt a long-term incentive program for senior executives and key employees within the Orexo group. The resolution also included resolution regarding authorisation for the board of directors to resolve to issue Class C shares, authorisation for the board of directors to resolve to repurchase Class C shares and transfer of own ordinary shares. Complete proposals regarding the resolutions by the annual general meeting in accordance with the above together with the presentation from the managing director's speech are available at Orexo's website, www.orexo.com. For more information, please contact: Nikolaj Sørensen, CEO, or Henrik Juuel, EVP/CFO Tel: + 46 (0)18 780 88 88, e-mail: ir@orexo.com About Orexo Orexo is a specialty pharmaceutical company commercializing its proprietary product Zubsolv® for treatment of opioid dependence in the US. Zubsolv is an advanced formulation of buprenorphine and naloxone using Orexo’s unique knowledge and expertise in sublingual drug delivery. R&D is focusing on reformulation of known substances to new improved products that meet great unmet medical needs by using its patented proprietary technologies. Orexo’s share is listed on Nasdaq Stockholm Exchange Mid Cap (STO:ORX) and is available as ADRs on OTCQX (ORXOY) in the US. Orexo’s global headquarters and R&D are based in Uppsala, Sweden. For information about Orexo please visit www.orexo.com. Note: This is information that Orexo AB (publ.) is required to disclose pursuant to the Swedish Securities Markets Act. The information was provided for public release on April 15, 2016 at 7:30 p.m. CET.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Altea Targets US Market, Appoints Rodrick VP Amid Expansion

Wading into the murky waters of U.S. healthcare insurance isn't for the faint of heart, but Altea's making its move. Backed by MISSION, they're banking on a niche strategy by tapping veteran Justin Rodrick as Vice President. Their tactic? Aim squarely at the under-served segment of small to mid-sized medical and healthcare facilities. The play's bold, and if Rodrick's got...

Navigating Home Care: What Families Need to Know

Peeking into the Home Care Playbook The process of starting home care isn't some mind-boggling puzzle. For families in Northeastern Pennsylvania, things kick off with a cordial chinwag with a care coordinator—no paperwork chains or Kafkaesque contracts right off the bat. Now, if you've got someone in need of care, this gives you time to shove all your questions onto the...

Innovative Trial Targets Drug Resistance in Lung Cancer

The Battle Against Drug Resistance Heats Up Folks, we're in a never-ending fight here against one of the toughest adversaries out there: lung cancer. And lemme tell ya, when drugs show resistance, it's like trying to punch a ghost. But there’s a fresh wind blowing, as Dr. Bobak Parang steps up to the plate with a $620K grant aimed squarely at tackling drug resistance in...

Kimberly-Clark Extends Kenvue Notes Exchange Deadline

Deadline Extended for Kenvue's Noteholders In the wild world of corporate finance, the only thing more unpredictable than the weather is a boardroom decision. Kimberly-Clark (NASDAQ: KMB) just threw one such curveball by extending the deadline on their exchange offers for Kenvue Notes to November 2, 2026. Seems like 5 p.m. New York time is the new witching hour for this...

Epilepsy Market's Explosive Growth Forecasted to 2036

It's a wild world out there for epilepsy treatments—like a relentless bull run with everyone eyeing the prize. The latest buzz points to a fat 2036 forecast for this sector, driven by a mix of standout technologies and breakthrough therapies. You'd be a fool to blink and miss it. Rising Numbers Stir the Market The numbers, oh boy, they're climbing. In 2025, about 7...

Don Silvestri: NFL Vet's Service Legacy Continues

More Than Just a Debt Guru It's not every day you see a former NFL player shifting gears so smoothly into the corporate world, and then to community service like a missile lock. But that's exactly what Don Silvestri, president of Debt.com, has done. Dragging a hefty reputation as a placekicker for teams like the New York Jets and the Buffalo Bills, he's now making...

CORE Embraces Tech to Boost Organ Donation Efforts

Innovation Meets Organ Donation Out of all the business moves you hear about, this one rings loud because it doesn’t just move the needle on a spreadsheet—it moves the needle on life or death. The Center for Organ Recovery & Education (CORE) is stepping into the future with a high-tech touch to enhance their lifesaving mission. Partnering with InVita Healthcare...

MillerKnoll's 3D Push: Legacy Meets Innovation

Bringing the Classics to the Digital Frontier Here's what's lighting a fire under the world of high-end furniture: MillerKnoll's got its eye on the prize by jazzing up Knoll.com with shiny new 3D product configurators. It's like taking a century's worth of design stuffiness and spinning it into the future, ready to dazzle a whole new set of eyeballs. Why This Move Matters...

Dotwork's AI Leap: Acquires Arcario to Revolutionize Strategy

Transformations in enterprise management are knocking at the door with Dotwork's latest move. Their strategic acquisition of Arcario Group aims to flip the lid on how companies tie strategies to their daily grind using AI. Let me level with you—this ain't about just spicing up some dashboards or workflows. We're talking about an enterprise-level overhaul in the very way...

Boeing's Third Quarter 2026: Progress Amid Losses

Boeing's Rocky Rollercoaster Ride This Quarter Man, if you want a case study on turbulence in the business world, look no further than Boeing's recent third-quarter performance. This juggernaut managed to clock in $24.2 billion in revenues, up 4% from last year, but it still can't seem to shake off its streak of red ink. We're talking a net loss of $116 million, or a GAAP...